89bio to Participate in Upcoming Investor Conferences
89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its management team's participation in two major healthcare investor conferences in May 2025:
1. BofA Securities 2025 Health Care Conference - Fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 PM ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Fireside chat scheduled for Tuesday, May 20, 2025, at 9:30 AM ET
Both presentations will be available via webcast on 89bio's investor relations website, with replays accessible for approximately 30 days after each event.
89bio (NASDAQ: ETNB), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e cardiometaboliche, ha annunciato la partecipazione del suo team di gestione a due importanti conferenze per investitori nel settore sanitario previste per maggio 2025:
1. BofA Securities 2025 Health Care Conference - Conversazione informale programmata per mercoledì 14 maggio 2025 alle 13:40 ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Conversazione informale programmata per martedì 20 maggio 2025 alle 9:30 ET
Entrambe le presentazioni saranno trasmesse in webcast sul sito web delle relazioni con gli investitori di 89bio, con le registrazioni disponibili per circa 30 giorni dopo ogni evento.
89bio (NASDAQ: ETNB), una compañía biofarmacéutica en etapa clínica especializada en terapias para enfermedades hepáticas y cardiometabólicas, ha anunciado la participación de su equipo directivo en dos importantes conferencias para inversores en el sector salud en mayo de 2025:
1. BofA Securities 2025 Health Care Conference - Charla informal programada para el miércoles 14 de mayo de 2025 a la 1:40 PM ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Charla informal programada para el martes 20 de mayo de 2025 a las 9:30 AM ET
Ambas presentaciones estarán disponibles vía webcast en el sitio web de relaciones con inversionistas de 89bio, con repeticiones accesibles durante aproximadamente 30 días después de cada evento.
89bio (NASDAQ: ETNB)는 간 및 심장대사 질환 치료제에 특화된 임상 단계의 바이오제약 회사로, 2025년 5월에 개최되는 두 개의 주요 헬스케어 투자자 컨퍼런스에 경영진이 참여할 예정임을 발표했습니다:
1. BofA Securities 2025 Health Care Conference - 2025년 5월 14일 수요일 오후 1시 40분(동부시간) 예정된 파이어사이드 채팅
2. 2025 RBC Capital Markets Global Healthcare Conference - 2025년 5월 20일 화요일 오전 9시 30분(동부시간) 예정된 파이어사이드 채팅
두 발표 모두 89bio 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 각 행사 후 약 30일간 다시보기 서비스를 이용할 수 있습니다.
89bio (NASDAQ : ETNB), une société biopharmaceutique en phase clinique spécialisée dans les thérapies pour les maladies du foie et cardiométaboliques, a annoncé la participation de son équipe de direction à deux grandes conférences pour investisseurs du secteur de la santé en mai 2025 :
1. BofA Securities 2025 Health Care Conference - Discussion informelle prévue le mercredi 14 mai 2025 à 13h40 ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Discussion informelle prévue le mardi 20 mai 2025 à 9h30 ET
Les deux présentations seront disponibles en webcast sur le site des relations investisseurs de 89bio, avec des rediffusions accessibles pendant environ 30 jours après chaque événement.
89bio (NASDAQ: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Leber- und kardiometabolische Erkrankungen spezialisiert hat, hat die Teilnahme seines Managementteams an zwei wichtigen Gesundheitsinvestoren-Konferenzen im Mai 2025 angekündigt:
1. BofA Securities 2025 Health Care Conference - Fireside Chat am Mittwoch, den 14. Mai 2025 um 13:40 Uhr ET
2. 2025 RBC Capital Markets Global Healthcare Conference - Fireside Chat am Dienstag, den 20. Mai 2025 um 9:30 Uhr ET
Beide Präsentationen werden per Webcast auf der Investor-Relations-Website von 89bio verfügbar sein, mit Wiederholungen, die etwa 30 Tage nach jeder Veranstaltung abrufbar sind.
- None.
- None.
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May:
BofA Securities 2025 Health Care Conference
Format: Fireside Chat
Date: Wednesday, May 14, 2025
Time: 1:40 PM ET
2025 RBC Capital Markets Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 9:30 AM ET
The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What investor conferences will ETNB present at in May 2025?
When is 89bio's presentation at the BofA Securities Healthcare Conference 2025?
How can investors access 89bio's conference presentations?
What is 89bio's main business focus?
